Estado del arte en primera línea de CPNM en pacientes sin mutaciones Driver Monoterapia vs combinación

9 / 54

Confirmed Objective Response Rate: KEYNOTE-024 Study
Assessed per RECIST v1.1 by blinded, independent central review.
Data cut-off: May 9, 2016.
0
10
20
30
40
50
60
ORR, % (95% CI)
Δ17%
P = 0.0011
45%
28%
PR
CR
n = 6
n = 63
n = 41
n = 1
Reck M, et al. NEJM 2016
10,3 vs 6 months